Towards the development of new effective antipsychotics
- Authors: Miroshnichenko I.I.1
-
Affiliations:
- Mental Health Research Center
- Issue: Vol 29, No 13 (2022)
- Pages: 59-61
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321131
- DOI: https://doi.org/10.18565/pharmateca.2022.13.59-61
- ID: 321131
Cite item
Open Access
Access granted
Abstract
Despite the fact that antipsychotic drugs have been known for a long time, the problem of finding new effective drugs really remains relevant. This article summarizes recent advances and failures in clinical trials for new antipsychotics. The Food and Drug Administration recently approved two new antipsychotic drugs USA (FDA). The combination form of olanzapine and samidorphan is intended to mitigate the side effects associated with the use of olanzapine. Another drug is lumateperone, which has the potential to treat patients with severe metabolic side effects. The efficacy and safety of the combined use of xanomeline and trospium in patients with schizophrenia are currently being studied. New indications of existing drugs for the treatment of schizophrenia are also considered.
Keywords
Full Text
About the authors
Igor I. Miroshnichenko
Mental Health Research Center
Email: igormir@psychiatry.ru
Dr. Sci. (Med.), Head of the Laboratory of Pharmacokinetics Moscow, Russia
References
- Lally J., MacCabe J.H. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114:169-79. doi: 10.1093/bmb/ldv017.
- Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10:515-31. doi: 10.1517/14728222.10.4.515.
- Wagner E, Siafis S., Fernando P, et al. Efficacy and safety of clozapine in psychotic disorders - a systematic quantitative metareview. Transl Psychiatry. 2021;11(1):487. Doi: 10.1038/ s41398-021-01613-2.
- Данилов Д.С. Классификация антипсихотических средств и их значение для выбора терапии шизофрении (к 60-летию появления нейролептиков). Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(10):91-100.
- Weston-Green K. Antipsychotic drug development: from historical evidence to fresh perspectives. Front Psychiatry. 2022;13:903156. Doi: 10.3389/ fpsyt.2022.903156.
- Vassilopoulou E., Efthymiou D., Papatriantafyllou E, et al. Long term metabolic and inflammatory effects of second-generation antipsychotics: a study in mentally disordered offenders. J Pers Med. 2021;11:1189. doi: 10.3390/jpm11111189.
- Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuro-Psychopharmacol Biol Psychiatry. 2004;28:1213-19. Doi: 10.1016/j. pnpbp.2004.06.020.
- Pahwa M, Sleem A., Elsayed O.H., et al. New antipsychotic medications in the last decade. Curr Psych Rep. 2021;23:87. doi: 10.1007/s11920-021-01298-w.
- Wong D.F., Raoufinia A., Bricmont P, et al. An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. Eur J Clin Pharmacol. 2021;77:717-25. doi: 10.1007/s00228-020-03021-9.
- Mailman R., Murthy V Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16:488-501. doi: 10.2174/138161210790361461.
- Tariot FIN., Ballard C., Devanand D.P, et al. Pimavanserin and dementia-related psychosis. Lancet. Neurol. 2022;21:114-15. Doi: 10.1016/ S1474-4422(21)00466-X.
- Lobo M.C, Whitehurst TS., Kaar S.J., Howes O.D. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022;132:324-61. Doi: 10.1016/j. neubiorev.2021.11.032.
- Greenwood J., Acharya R.B., Marcellus V, Rey J.A. Lumateperone: a novel antipsychotic for schizophrenia. Ann Pharmacother. 2021;55:98-104. doi: 10.1177/1060028020936597.
- Paik J. Olanzapine/samidorphan: first approval. Drugs. 2021;81:1431-36. doi: 10.1007/s40265-021-01568-0.
- Rehan ST., SiddiquiA.H., Khan Z., et al. Samidorphan/ olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. An Med Surg (Lond). 2022;79:104115. Doi: 10.1016/j. amsu.2022.104115.
- Weiden PJ., Breier A., Kavanagh S., et al. Antipsychotic efficacy of KarXT (xanomeline-trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study. J Clin Psych. 2022;11(83):21m14316. doi: 10.4088/JCP21m14316.
- Brannan S.K., Sawchak S., Miller A.C., et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Eng J Med. 2021;384:717-26. Doi: 10.1056/ NEJMoa2017015.
- Opler L.A., Medalia A., Opler M.G., et al. Pharmacotherapy of cognitive deficits in schizophrenia. CNS Spectrums. 2014;19:142-56. doi: 10.1017/S1092852913000771.
- Moсолов С.Н., Смулевич А.Б., Незнанов Н.Г и др. Применение агонистов mGlu2/3 - новый подход к терапии шизофрении: результаты рандомизированного двойного слепого исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;110(7):16-23. [Mosolov S.N., Smulevich A.B., Neznanov N.G., et al. The use mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;110(7):16-23. (In Russ.)].
- Мирошниченко И.И., Вальдман Е.А., Кузьмин И.И. Новое предназначение старых лекарств. Разработка и регистрация лекарственных средств. 2022. В печати. [Miroshnichenko I.I., Valdman E.A., Kuz'min I.I. Old drugs, new indications. Razrabotka i registratsiya lekarstvennykh sredstv. 2022. In press. (In Russ.)].
- Romero-Miguel D., Lamanna-Rama N., Casquero-Veiga M., et al. Minocycline in neurodegenerative and psychiatric diseases: An update. Eur J Neurol. 2021;28:1056-81. doi: 10.1111/ene.14642.
- Cakici N., van Beveren N. J. M., Judge-Hundal G., et al. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a metaanalysis. Psychol Med. 2019;49:2307-19. doi: 10.1017/S0033291719001995.
Supplementary files
